Synergistic Peptide Blend
Growth factor with mitochondrial support.
A strategic combination of IGF-1 LR3 for anabolic signaling and MOTS-C for mitochondrial optimization. This blend delivers sustained muscle growth through direct IGF-1 receptor activation while enhancing cellular energy production, metabolic flexibility, and recovery capacity—addressing both muscle protein synthesis and the energetic demands of performance.
2
Peptide Blend
1mg/10mg
Dosage Ratio
Dual
Mechanism
22+
BHRC Locations
Blend Components
This synergistic blend combines two complementary peptides for enhanced muscle growth and metabolic optimization.
1mg per dose
Primary Benefits
Promotes muscle protein synthesis, supports recovery, and enhances cell growth through long-acting IGF-1 receptor activation.
10mg per dose
Primary Benefits
Enhances cellular energy, improves metabolic function, supports insulin sensitivity, and promotes exercise response through mitochondrial regulation.
The Science
This advanced peptide blend combines IGF-1 LR3, a long-acting insulin-like growth factor analog, with MOTS-C, a mitochondrial-encoded peptide that regulates cellular metabolism. Together, they create a synergistic protocol addressing both anabolic signaling and metabolic efficiency.
IGF-1 LR3 provides sustained muscle protein synthesis and satellite cell activation through direct IGF-1 receptor engagement, while MOTS-C enhances mitochondrial function, improves insulin sensitivity, and supports metabolic flexibility. This dual mechanism supports muscle growth while optimizing the cellular energy systems required for performance and recovery.
The combination is particularly effective for individuals seeking comprehensive body composition optimization—promoting lean muscle gain through anabolic pathways while enhancing fat metabolism and energy production through mitochondrial enhancement. At BHRC, we use this blend for patients pursuing peak performance and metabolic health.
Book a Consultation
How It Works
This blend activates both anabolic and metabolic pathways—IGF-1 LR3 drives muscle protein synthesis while MOTS-C optimizes mitochondrial function for enhanced energy production and metabolic health.
IGF-1 LR3 binds to muscle IGF-1 receptors, triggering PI3K/Akt and MAPK pathways that promote protein synthesis, satellite cell proliferation, and muscle hypertrophy.
MOTS-C regulates mitochondrial function, improves oxidative phosphorylation efficiency, and enhances cellular ATP production for sustained energy and recovery.
MOTS-C enhances insulin sensitivity and glucose metabolism while IGF-1 LR3 increases nutrient partitioning to muscle—creating optimal conditions for lean mass gains and fat utilization.
Clinical Benefits
IGF-1 LR3 drives rapid muscle protein synthesis and hypertrophy while MOTS-C ensures adequate cellular energy to support sustained anabolic activity and training intensity.
Dual support for muscle repair through IGF-1 receptor pathways and enhanced mitochondrial ATP production accelerates recovery between training sessions and reduces fatigue.
MOTS-C enhances insulin sensitivity and glucose metabolism while improving fat oxidation—supporting lean mass gains with improved nutrient partitioning and body composition.
Mitochondrial enhancement from MOTS-C increases cellular ATP production and oxidative capacity, supporting improved exercise performance and sustained energy throughout training.
The combination addresses both anabolic signaling and metabolic function simultaneously—creating a more comprehensive approach to performance enhancement than single-peptide protocols.
MOTS-C provides protective effects on mitochondria while supporting metabolic health markers including improved insulin sensitivity, glucose regulation, and reduced oxidative stress.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Meet with our physician to assess your performance goals, metabolic health, and determine if this blend is appropriate for your needs.
Comprehensive testing including IGF-1, glucose, insulin, metabolic panel, and mitochondrial markers to establish baseline health status.
Personalized treatment plan with precise dosing for both peptides, injection training, cycle structure, and lifestyle recommendations for optimal synergy.
Regular follow-ups with progress tracking, lab monitoring of both anabolic and metabolic markers, and protocol adjustments to ensure safe, effective results.
Safety & Candidacy
This blend combines well-researched peptides with documented anabolic and metabolic effects. While not FDA-approved for performance enhancement, it’s used in supervised medical protocols for body composition and metabolic optimization.
4-6wks
Typical cycle duration with proper medical monitoring and planned rest periods for both peptides
1x/day
Once-daily subcutaneous administration of the combined blend formulation
Questions
This combination addresses both anabolic signaling and metabolic function. IGF-1 LR3 drives muscle protein synthesis and growth while MOTS-C optimizes mitochondrial efficiency and energy production. Together, they create a synergistic effect—building muscle while ensuring your cells have the metabolic capacity to support that growth, recovery, and performance.
The blend is typically administered as a single subcutaneous injection once daily. Our clinical team provides comprehensive training on proper reconstitution, injection technique, site rotation, and storage of both peptides. Some protocols may use specific timing relative to training or meals to optimize nutrient partitioning and metabolic effects.
Users typically report accelerated muscle growth, improved energy levels and endurance, enhanced recovery between sessions, better body composition with lean mass gains, increased training capacity, and improved metabolic markers. Results are maximized when combined with proper training, nutrition, and adequate protein intake. Individual responses vary based on training status, diet, genetics, and baseline metabolic health.
Typical cycles range from 4-6 weeks under medical supervision, followed by an off period to maintain receptor sensitivity for both peptides. Your physician will design a protocol based on your goals, response to therapy, and monitoring data including glucose metabolism, IGF-1 levels, and metabolic health markers.
Potential side effects from IGF-1 LR3 include hypoglycemia, joint discomfort, and water retention. MOTS-C is generally well-tolerated but may cause mild injection site reactions. The combination may affect blood glucose and insulin sensitivity. Blood glucose monitoring is important, especially for those with diabetes or metabolic concerns. All use should be under physician supervision with regular lab monitoring of both anabolic and metabolic markers.
Ideal candidates are adults seeking comprehensive performance enhancement—both muscle growth and metabolic optimization—who have plateaued with conventional approaches. Those with metabolic concerns, fatigue, or poor recovery despite adequate training may particularly benefit from the mitochondrial support. Contraindications include active malignancy, uncontrolled diabetes, pregnancy, or history of certain cancers. A physician consultation with comprehensive lab work is required to assess candidacy.
Monitoring includes regular glucose testing, IGF-1 levels, metabolic panels, insulin sensitivity markers, mitochondrial function indicators, and clinical assessments. Body composition tracking via DEXA or other methods quantifies muscle gain and fat loss. Your physician schedules follow-ups every 2-4 weeks during active cycles to ensure safety, assess metabolic response, and optimize results from both peptides.
Get Started
Schedule a consultation with our medical team to learn if IGF-LR3/MOTS-C blend peptide therapy is right for your muscle growth and metabolic optimization goals.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This peptide blend is not FDA-approved for performance enhancement or metabolic optimization. Use is off-label and administered under medical supervision for research and therapeutic purposes. Results vary by individual based on genetics, training, nutrition, and adherence. IGF-1 LR3 may affect glucose metabolism and insulin sensitivity. Contraindicated in patients with active malignancy, uncontrolled diabetes, or certain medical conditions. A consultation with our medical team and comprehensive laboratory testing are required to determine if this therapy is appropriate for you. This product is intended for use only under qualified medical supervision.
